NEW YORK (GenomeWeb News) – Nanosphere today said that the US Food and Drug Administration has cleared for marketing its CYP2C19 test to run on the firm's Verigene System.

The Verigene CYP2C19 Test was cleared as an aid to physicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. It identifies the CYP2C19 *2, *3, and *17 variations from a whole blood sample in less than 2.5 hours, said Nanosphere.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.